Plain-English translation of NCT07275840 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a new medication called IBI302 that is injected directly into the eye to treat wet age-related macular degeneration (a common cause of vision loss in older adults). Researchers want to learn whether this treatment can help slow vision loss and improve sight in people whose eyes show signs of abnormal blood vessel growth under the retina.
Current treatments for this condition require repeated injections and don't work well for everyone. This trial is exploring whether this medication could offer patients a better treatment option with the potential for improved vision outcomes.
You likely qualify if…
You likely don't qualify if…
You would receive injections of the medication directly into your eye at a hospital or eye clinic. The study involves multiple visits to monitor how well the treatment works and to check for any side effects. You will have your vision measured and your eye examined regularly throughout the trial to see if the medication helps improve or stabilize your sight.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Innovent Biologics Technology Limited (Shanghai R&D Center)
Enrollment target
~800 participants
Started
December 2025
Primary completion
August 2026
Age range
50 Years and older
Last updated on clinicaltrials.gov in January 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Yating Liu
Innovent Biologics Technology Limited (Shanghai R&D Center)
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.